Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Stetson

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker AssessmentMark Roschewski, Manish R Patel, Patrick M Reagan, et al.
JCO Precision Oncology|July 12, 2021
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of HealthP Mickey Williams, Thomas Forbes, Steven P Lund, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast CancerMarla Lipsyc-Sharf, Elza C de Bruin, Katheryn Santos, et al.
Clinical and Translational Science|December 26, 2025
Lexicon for Clonal Hematopoiesis in Liquid BiopsyRobert Tell, Ahmet Zehir, Andrew T Anfora, et al.
JCO Precision Oncology|May 11, 2026
Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based Circulating Tumor DNA Assays, Version 2.0Angela Silvestro, Jonathan Baden, Kevin Billings, et al.
Cancer Research|April 15, 2015
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical ModelsCatherine A Eberlein, Daniel Stetson, Aleksandra A Markovets, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT TrialPeter Schmid, Jacinta Abraham, Stephen Chan, et al.
JCO Precision Oncology|May 1, 2024
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast CancerJacqueline A Shaw, Karen Page, Evie Wren, et al.
The Journal of Molecular Diagnostics : JMD|February 24, 2023
Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests: A Blood Profiling Atlas in Cancer (BLOODPAC) Community StudyKyle M Hernandez, Kelli S Bramlett, Phaedra Agius, et al.
Genome Biology|June 29, 2022
Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samplesYifan Zhang, Thomas M Blomquist, Rebecca Kusko, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 26, 2023
Phase I Study of Acalabrutinib Plus Danvatirsen (AZD9150) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma Including Circulating Tumor DNA Biomarker AssessmentMark Roschewski, Manish R Patel, Patrick M Reagan, et al.
JCO Precision Oncology|July 12, 2021
Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of HealthP Mickey Williams, Thomas Forbes, Steven P Lund, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 6, 2022
Circulating Tumor DNA and Late Recurrence in High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast CancerMarla Lipsyc-Sharf, Elza C de Bruin, Katheryn Santos, et al.
Clinical and Translational Science|December 26, 2025
Lexicon for Clonal Hematopoiesis in Liquid BiopsyRobert Tell, Ahmet Zehir, Andrew T Anfora, et al.
JCO Precision Oncology|May 11, 2026
Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based Circulating Tumor DNA Assays, Version 2.0Angela Silvestro, Jonathan Baden, Kevin Billings, et al.
Cancer Research|April 15, 2015
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical ModelsCatherine A Eberlein, Daniel Stetson, Aleksandra A Markovets, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT TrialPeter Schmid, Jacinta Abraham, Stephen Chan, et al.
JCO Precision Oncology|May 1, 2024
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast CancerJacqueline A Shaw, Karen Page, Evie Wren, et al.
The Journal of Molecular Diagnostics : JMD|February 24, 2023
Contrived Materials and a Data Set for the Evaluation of Liquid Biopsy Tests: A Blood Profiling Atlas in Cancer (BLOODPAC) Community StudyKyle M Hernandez, Kelli S Bramlett, Phaedra Agius, et al.
Genome Biology|June 29, 2022
Deep oncopanel sequencing reveals within block position-dependent quality degradation in FFPE processed samplesYifan Zhang, Thomas M Blomquist, Rebecca Kusko, et al.
Pageof 3